The hypoglycemic risk of glyburide (glibenclamide) compared with modified-release gliclazide
Clemens KK, McArthur E, Dixon SN, Fleet JL, Hramiak I, Garg AX. Can J Diabetes. 2015; 39(Suppl 4):32-40.
Publications
Examining exposure misclassification of oral bisphosphonate therapy and the associated fracture risk: a cohort study
Burden AM, Gruneir A, Paterson JM, Cadarette SM. Adv Pharmacoepidemiol Drug Saf. 2015; 4:4.
Osteoporosis management and fractures in the Métis of Ontario, Canada
Jandoc R, Jembere N, Khan S, Russell SJ, Allard Y, Cadarette SM. Arch Osteoporos. Epub 2015 Apr 25.
Safety of valproic acid in patients with chronic obstructive pulmonary disease: a population-based study
Antoniou T, Yao Z, Camacho X, Mamdani MM, Juurlink DN, Gomes T. Pharmacoepidemiol Drug Saf. 2015; 24(3):256-61. Epub 2015 Feb 5.
Initial uptake of the Ontario Pharmacy Smoking Cessation Program
Wong L, Burden AM, Liu YY, Tadrous M, Pojskic N, Dolovich L, Calzavara A, Cadarette SM. Can Pharm J. 2015; 148(1):29-40. Epub 2014 Dec 17.
Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data
Burden AM, Paterson JM, Gruneir A, Cadarette SM. Pharmacoepidemiol Drug Saf. 2015; 24(1):67-74. Epub 2014 Oct 21.
Adverse cardiac events in older patients receiving venlafaxine: a population-based study
Ho JM, Gomes T, Straus SE, Austin PC, Mamdani M, Juurlink DN. J Clin Psychiatry. 2014;75(6):e552-8.
Use of niacin in the United States and Canada
Jackevicius CA, Tu JV, Ko DT, de Leon N, Krumholz HM. JAMA Intern Med. 2013; 173(14):1379-81. Epub 2013 Jun 10.
Variation in the days supply field for osteoporosis medications in Ontario
Burden AM, Huang A, Tadrous M, Cadarette SM. Arch Osteoporos. 2013; 8:128. Epub 2013 Mar 9.
Effectiveness of community-wide and individual high-risk strategies to prevent diabetes: a modelling study
Manuel DG, Rosella LC, Tuna M, Bennett C, Stukel TA. PLoS One. 2013; 8(1):e52963. Epub 2013 Jan 4.